Point72 Asset Management
CLYM

Point72 Asset Management’s Climb Bio CLYM Stock Holding History

Point72 Asset Management’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$405K Sell
59,090
-657,590
-92% -$3.79M ﹤0.01% 3221
2025
Q4 		$2.87M Buy
+716,680
New +$1.72M ﹤0.01% 2253
2024
Q4 		– Sell
-590,946
Closed -$3.01M – 2547
2024
Q3 		$3.01M Buy
+590,946
New +$4.18M 0.01% 1041
2022
Q2 		– Sell
-142,333
Closed -$1.19M – 1690
2022
Q1 		$1.19M Buy
+142,333
New +$1.33M ﹤0.01% 937

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Point72 Asset Management's CLYM Position: Q1 2026 in Review

Point72 Asset Management reduced its Climb Bio (CLYM) stake by 92% in Q1 2026, selling an estimated $3.79M and leaving 59,090 shares worth $405K. The position accounts for ﹤0.01% of the portfolio, ranked #3221.

Point72 Asset Management first reported a position in CLYM in Q1 2022 and has held it in 4 quarters since. The position peaked at $3.01M in Q3 2024. 80 funds tracked by Wall St. Rank hold CLYM as of Q1 2026.

  • Point72 Asset Management held 59,090 shares of Climb Bio worth $405K as of Q1 2026.
  • Point72 Asset Management sold 657,590 Climb Bio shares in Q1 2026, an estimated $3.79M.
  • Climb Bio made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #3221 holding.
  • Point72 Asset Management first reported a position in Climb Bio in Q1 2022 and has held it in 4 quarters since.
  • Point72 Asset Management's Climb Bio position peaked at $3.01M in Q3 2024.
  • 80 funds tracked by Wall St. Rank held Climb Bio as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.